IRCCS Humanitas Research Hospital, Milan, Italy.
MOX lab, Department of Mathematics, Politecnico di Milano, Milano, Italia.
Acta Oncol. 2022 May;61(5):553-559. doi: 10.1080/0284186X.2022.2042475. Epub 2022 Feb 24.
to find clinical features that can predict prognosis in patients with oligometastatic disease treated with stereotactic body radiotherapy (SBRT).
Patients with less than 5 metastases in less than 3 different body sites were included in the analysis. Various clinical and treatment parameters were analyzed to create a Cox proportional hazard model for Overall Survival (OS). Subsequently, significant variables were used to create a score.
997 patients were analyzed. Median OS was 2.61 years, 1 and 3 years OS was respectively 85% and 43%. Location of the primary tumor, performance status, site of irradiated metastases, presence of extratarget non irradiated lesions and RT dose were significant prognostic factors for OS. These parameters were used to create a score and to distinguish three different classes, with median OS of 5.67 years in low risk, 2.47 years in intermediate risk and 1.82 years in high risk group.
moving from easily accessible clinical parameters, a score was created to help the physician's decision about the better treatment or combination of treatments for the individual patient.
寻找能够预测接受立体定向体部放射治疗（SBRT）治疗的寡转移疾病患者预后的临床特征。
本分析纳入了转移灶少于 5 个且分布于不超过 3 个不同部位的患者。分析了各种临床和治疗参数，以建立用于总生存（OS）的 Cox 比例风险模型。随后，使用有意义的变量建立评分。
共分析了 997 例患者。中位 OS 为 2.61 年，1 年和 3 年 OS 分别为 85%和 43%。原发肿瘤部位、体力状况、照射转移部位、是否存在非照射靶外病变以及放疗剂量是 OS 的显著预后因素。这些参数被用于建立评分，并区分出三个不同的类别，低危组的中位 OS 为 5.67 年，中危组为 2.47 年，高危组为 1.82 年。
通过从易于获取的临床参数出发，创建了一个评分，以帮助医生为个体患者做出更好的治疗或治疗组合决策。
